Publications
Sims, J. D., Taguiam, J. M., Alonso-Valenteen, F., Markman, J., Agadjanian, H., Chu, D., Lubow, J., Abrol, R., Srinivas, D., Jain, A., Han, B., Qu, Y., Mirzadehgan, P., Hwang, J-Y., Rentsendorj, A., Chung, A., Lester, J., Karlan, B. Y., Gray, H. B., Gross, Z., Giuliano, A., Cui, X., Medina-Kauwe L. K. (2018). Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. Journal of Controlled Release, 271,127-138. https://doi.org/10.1016/j.jconrel.2017.12.024
Beach, J.A., Aspuria, P-J. P., Cheon, D-J., Lawrenson, Agadjanian, H., Walsh, C., Karlan, B.Y., & Orsulic, S. (2015). Sphingosine kinase 1 is required for TGF-? mediated fibroblastto-myofibroblast differentiation in ovarian cancer. Oncotarget, 7 (4), 4167-4182.
Cohen, J. G., Prendergast, E., Geddings, J. E., Walts, A. E., Agadjanian, H., Hisada, Y., Karlan B.Y., Mackman N., & Walsh, C. S. (2017). Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecologic Oncology, 146(1), 146-152. doi:10.1016/j.ygyno.2017.04.021
Liu, Z., Beach, J.A., Agadjanian, H., Jia, D., Aspuria, P-J., Karlan, B.Y., & Orsulic, S. (2015). Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecologic Oncology, 139, 394-400. DOI:10.1016/j.ygyno.2015.08.026 · 3.77
Taylor-Harding, B., Aspuria, P-J, Agadjanian, H., Cheon, D-J, & Wiedemeyer, W.R. (2014). CyclinE and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget, 6 (2), 696-714.
Diaz, E., Agadjanian, H., Nassanian, H., Walts, A., Miller, C., Karlan, B., Osulic, S., & Walsh C. (2013). PI3K pathway activation, thromboembolism and survival in ovarian cancer cell carcinoma. Gynecologic Oncology, 130(1) e.128. DOI:10.1016/j.ygyno.2013.04.367
Agadjanian, H., Chu, D., Hwang, J.Y., Wachsmann-Hogiu, S., Rentsendorj, A., Song, L., Valluripalli, V., Lubow, J., Ma, J., Sharifi, B., Farkas, D.L.,& Medina-Kauwe, L.K. (2012). Chemotherapy targeting by DNA capture in viral protein particles. Nanomedicine, 7(3), 335-352. DOI: 10.2217/nnm.11.104
Taylor-Harding, B., Agadjanian, H., Nassanian, H., Kwon, S., Guo, X., Miller, C., & Karlan, B.Y. Orsulic, S., and Walsh, C.S. (2012). Indole-3-carbinol synergistically sensitizes ovarian cancer cells to bortezomib treatment. British Journal of Cancer, 106, 333 – 343.
Fleming, N. D., Agadjanian, H., Nassanian, H., Miller, C. W., Orsulic, S., Karlan B. Y., & Walsh C. S. (2012). Xeroderma Pigmentosum Complementation Group C Single-Nucleotide Polymorphisms in the Nucleotide Excision Repair Pathway Correlate With Prolonged Progression-Free Survival in Advanced Ovarian Cancer. Cancer, 118, 689-697.
Liu Z, Beach JA, Agadjanian H, Jia D., Aspuria P, Karlan BY, Orsulic S. (2016). Abstract B64: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B64
Taylor-Harding B, Agadjanian H, Aspuria P, Cheon, D., Mizuno T, Greenberg D, Allen JR, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. (2014). Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance Cancer Research. 74: 678-678. DOI: 10.1158/1538-7445.Am2014-678
Agadjanian H, Cheon D., Diaz E, Laury A, Miller C, Karlan B, Orsulic S, Walsh C. (2013). Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research. 73: 329-329. DOI: 10.1158/1538-7445.Am2013-329
Taylor-Harding B, Agadjanian H, Orsulic S, Walsh C, Karlan BY, Wiedemeyer W. (2013). Abstract 1749: Cell cycle requirements shape ovarian cancer progression. Cancer Research. 73: 1749-1749. DOI: 10.1158/1538-7445.Am2013-1749
Taylor-Harding B, Agadjanian H, Aspuria PJ, Mizuno T, Cheon D., Orsulic S, Karlan B, Walsh C, Wiedemeyer WR. (2013). Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B48
Presentations
Walsh, C., Nassanian, H., Agadjanian, H., Miller, C., Orsulic, S., & Karlan, B. (2015).
Abstract BIOL-1348. No association between PARK2 and BRCA1-associated gynecologic cancers. Cancer Research, 21(16 Supplement): POSTER-BIOL-1348. DOI:10.1158/1557-3265.OVCASYMP14
Taylor-Harding, B., Agadjanian, H., Aspuria, P-J., Mizuno, T., Cheon, D-J., Orsulic, S., Karlan, B., Walsh, C., & Wiedemeyer, W.R. (2014). Abstract B48. Targeting chemo-resistance in CCNE1-amplified ovarian cancer. Clinical Cancer Research, 19, B48.
Agadjanian, H., Cheon, D-J, Diaz, E., Laury, A., Miller, C., Orsulic, S., & Walsh C. (2013). Abstract 329. A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research, 73(8 supplement) p.329.
Taylor-Harding, B., Agadjanian, H., Orsulic, S., Walsh, C., Karlan, B., & Wiedemeyer, W.R. (2013). Abstract 1749. Cell Cycle requirements shape ovarian cancer progression. Cancer Research, 73, p.1749.
By continuing to use our site, you consent to this condition of use. For more information, please review our Privacy Policy.